182 related articles for article (PubMed ID: 3261498)
1. In vitro inhibition of the classical and alternate pathways of activation of human complement by N acetyl aspartyl glutamic acid (NAAGA).
Etievant M; Leluc B; David B
Agents Actions; 1988 Jun; 24(1-2):137-44. PubMed ID: 3261498
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of in vitro inhibition of activation of the classical and alternative pathways of human complement by the magnesium and sodium salts of the anti-inflammatory peptide N-acetyl-aspartyl-glutamic acid (NAAGA).
Feuillard J; Maillet F; Goldschmidt P; Weiss L; Kazatchkine MD
Agents Actions; 1991 Mar; 32(3-4):343-6. PubMed ID: 1862751
[TBL] [Abstract][Full Text] [Related]
3. In vitro inhibition of the classical pathway of human complement by a natural microbial product, colistin sulphate.
Asghar SS; de Koster A; van der Helm HJ
Biochem Pharmacol; 1986 Sep; 35(17):2917-21. PubMed ID: 3638137
[TBL] [Abstract][Full Text] [Related]
4. [A peptide (a magnesium salt of N-acetyl (alpha, beta)-aspartyl-glutamic acid). Demonstration of the protection against local cellular destruction induced by in situ complement activation].
Chevance LG; Etiévant M
J Pharmacol; 1986; 17(4):676-85. PubMed ID: 3560976
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cleavage of the third component of human complement (C3) by its small cleavage fragment, C3a: inhibition occurs with the classical-pathway, but not the alternative-pathway, C3 convertase.
Strunk RC; Webster RO
Mol Immunol; 1985 Jan; 22(1):37-43. PubMed ID: 3871899
[TBL] [Abstract][Full Text] [Related]
6. Trypanosoma lewisi: restriction of alternative complement pathway C3/C5 convertase activity.
Sturtevant JE; Balber AE
Exp Parasitol; 1987 Jun; 63(3):260-71. PubMed ID: 3556206
[TBL] [Abstract][Full Text] [Related]
7. Effect of sodium nitroprusside on complement activation induced by cardiopulmonary bypass: a clinical and experimental study.
Seghaye MC; Duchateau J; Grabitz RG; Wolff T; Marcus C; Engelhardt W; Hörnchen H; Messmer BJ; von Bernuth G
J Thorac Cardiovasc Surg; 1996 Apr; 111(4):882-92. PubMed ID: 8614150
[TBL] [Abstract][Full Text] [Related]
8. Polyglycolic acid-induced inflammation: role of hydrolysis and resulting complement activation.
Ceonzo K; Gaynor A; Shaffer L; Kojima K; Vacanti CA; Stahl GL
Tissue Eng; 2006 Feb; 12(2):301-8. PubMed ID: 16548688
[TBL] [Abstract][Full Text] [Related]
9. Secreted pH-regulated antigen 1 of Candida albicans blocks activation and conversion of complement C3.
Luo S; Hartmann A; Dahse HM; Skerka C; Zipfel PF
J Immunol; 2010 Aug; 185(4):2164-73. PubMed ID: 20644161
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the classical and alternative pathways of human and guinea pig complement by pyran copolymer.
Webster GF; McArthur WP
Int Arch Allergy Appl Immunol; 1981; 66(3):304-9. PubMed ID: 6913544
[TBL] [Abstract][Full Text] [Related]
11. Formation and function of the classical and alternative pathways of complement.
Ogle JD; Ogle CK
Clin Physiol Biochem; 1983; 1(2-5):194-213. PubMed ID: 6241120
[No Abstract] [Full Text] [Related]
12. Synthetic peptide inhibitors of complement serine proteases--II. Effects on hemolytic activity and production of C3a and C4a.
Schasteen CS; McLafferty SA; Glover GI; Han CY; Mayden JC; Liu WS; Levine RP
Mol Immunol; 1988 Dec; 25(12):1269-75. PubMed ID: 3266292
[TBL] [Abstract][Full Text] [Related]
13. Eosinophil granule major basic protein regulates generation of classical and alternative-amplification pathway C3 convertases in vitro.
Weiler JM; Gleich GJ
J Immunol; 1988 Mar; 140(5):1605-10. PubMed ID: 3346544
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the classical and alternative pathways of the human complement system by glycosaminoglycan polysulfate.
de Messias IT; Mohren D; Kajdacsy-Balla A
J Investig Allergol Clin Immunol; 1994; 4(4):172-6. PubMed ID: 7850029
[TBL] [Abstract][Full Text] [Related]
15. Effect of RBCs on the activation of human complement by heparin-protamine complexes.
Shastri KA; Phillips MJ; Raza S; Logue GL; Rustagi PK
Blood; 1988 Jan; 71(1):36-40. PubMed ID: 3334899
[TBL] [Abstract][Full Text] [Related]
16. Relative inefficiency of terminal complement activation.
Bhakdi S; Fassbender W; Hugo F; Carreno MP; Berstecher C; Malasit P; Kazatchkine MD
J Immunol; 1988 Nov; 141(9):3117-22. PubMed ID: 3262681
[TBL] [Abstract][Full Text] [Related]
17. Effect of aspirin on the complement system in vitro.
Hänsch GM; Voigtländer V; Rother U
Int Arch Allergy Appl Immunol; 1980; 61(2):150-8. PubMed ID: 7351347
[TBL] [Abstract][Full Text] [Related]
18. Effect of N-acetyl-aspartyl-glutamate (Naaga) on in-vitro leukotriene synthesis by macrophage cell line P388D1.
Jambou D; Lapalus P
Int J Tissue React; 1990; 12(5):273-80. PubMed ID: 1983004
[TBL] [Abstract][Full Text] [Related]
19. Effect of a streptococcal preparation on the complement system.
Kato H; Yokoe N; Matsumura N; Nishida K; Ikezaki M; Hosokawa K; Hotta T; Takemura S; Yoshikawa T; Kondo M
Jpn J Exp Med; 1979 Oct; 49(5):343-50. PubMed ID: 529490
[TBL] [Abstract][Full Text] [Related]
20. Multiple effects of a diamidine (propamidine) on complement activation.
Vogt W; Hinsch B; Schmidt G; Von Zabern I
Immunology; 1979 Jan; 36(1):131-7. PubMed ID: 422224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
